FDA approves first interchangeable biosimilar insulin product
The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
Related News Articles
Headline
“Hospitals are the heart of communities across America for one fundamental reason: They support patients whenever, wherever and however they need care,” writes…
Blog
I have the distinct privilege of serving as chair of the American Hospital Association’s Foster G. McGaw Prize Committee, which awards a prize each year to one…
Headline
Doug Brown, partner with Manatt Health and current chair of the AHA’s Foster G. McGaw Prize Committee, discusses how hospitals are tackling food insecurity,…
Headline
Obesity rates for U.S. children and teenagers have reached record highs, while rates for adults had a slight decline, according to reports by the Centers for…
Blog
Digital tools are improving access to behavioral health care at a time when demand is increasing. Individuals can use digital access points to better…
Headline
A new AHA blog shares examples of hospitals and health systems working together with Area Agencies on Aging to address the social needs of older adults and…